BioAtla Investor Presentation Deck

Promising preclinical results with CAB-EpCAM x CAB-CD3 bispecific antibody in NHP and a colorectal cell line Tumor volume (mm³) 2500 2000 1500 1000 500 0 T 0 bicatla --Isotype x WT CD3 EpCAM x WT CD3 ACAB EpCAM x CAB CD3 10 20 30 40 Study Days MiXeno Model with HCT116 = Colorectal Cancer Cell Line 1mg/kg twice/week in mice (equivalent to 0.25mg/kg in non-human primates) MTD, maximum tolerate dose; NHP, non-human primate; WT = wild type; *from independent experiments. 50 ■ CAB-EpCAM x CAB-CD3 bispecific demonstrates efficient tumor shrinkage in a colorectal cancer cell line In non-GLP and GLP tox studies in NHP, dual selection results in high selectivity >160x higher therapeutic index MTD not reached (5mg/kg highest dose studied=NOAEL) No Cytokine release observed Long half-life in Cyno (~4 days) These promising results will enable IND submission and Phase 1 initiation for multiple solid tumors 2H2022 - ■ BioAtla| Overview 33

View entire presentation